Fluart Innovative Vaccines

Executive Summary

Fluart Innovative Vaccines is a Hungarian biopharmaceutical company founded in 1991 with a long-standing focus on influenza vaccine research, development, and manufacturing. Operating as a Contract Development and Manufacturing Organization (CDMO), the company provides integrated services from early discovery through commercial production, leveraging decades of expertise in viral vaccine platforms. Beyond its core vaccine business, Fluart is advancing preclinical R&D in bacteriophage therapy and serving the animal health and food industries, positioning itself as a versatile player in the infectious disease space. Despite a limited public profile and no disclosed funding rounds or valuation, the company's established CDMO operations suggest a sustainable revenue base supporting its internal pipeline.

Upcoming Catalysts (preview)

• Q3 2026Announcement of new CDMO contract for seasonal influenza vaccine production70% success
• TBDInitiation of Phase I clinical trial for a novel influenza vaccine candidate30% success
• Q3 2026European grant award for bacteriophage therapy development50% success